Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00290134 · ClinicalTrials.gov registry record · Phase 2
A Preliminary Clinical Study to Evaluate Fispemifene in the Treatment of Hypogonadism
A Phase 2 study of Hypogonadism, sponsored by QuatRx Pharmaceuticals Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 16
- Study locations
NCT00290134: Completed Phase 2 study of Hypogonadism, sponsored by QuatRx Pharmaceuticals Company.
NCT00290134 is a Phase 2 study of Hypogonadism that has completed, run by QuatRx Pharmaceuticals Company. The registered enrollment target is 100 participants, below the 115-participant average among 21 other Hypogonadism trials with a reported enrollment target (13% lower). The trial reports 16 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00290134, a Phase 2 study of Hypogonadism, has completed, sponsored by QuatRx Pharmaceuticals Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 16
- Study locations
Study Summary
The purpose of this study is to determine whether one or more fispemifene dose regimens are more effective than placebo in the treatment of hypogonadism in older men.
Conditions Studied
Interventions
- DRUG Fispemifene once daily for 4 weeks
Study Locations (16)
New York
- Clinical Research Site - Garden City
- Clinical Research Site - Poughkeepsie
- Clinical Research Site - Williamsville
Florida
- Clinical Research Site - New Port Richey
- Clinical Research Site - Tallahassee
Alabama
- Clinical Research Site - Huntsville
California
- Clinical Research Site - Modesto
Colorado
- Clinical Research Site - Aurora
Connecticut
- Clinical Research Site - Waterbury
Illinois
- Clinical Research Site - Peoria
Maryland
- Clinical Research Site - Greenbelt
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2006-02 |
| Est. Completion | 2007-10 |
| Phase | Phase 2 |
What the finished NCT00290134 record still lists
NCT00290134 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 115-participant average among 21 other Hypogonadism trials with a reported enrollment target (13% lower).
The record links to 1 condition, with Hypogonadism appearing as the primary indexed condition, and to 1 intervention - of which Fispemifene once daily for 4 weeks is the first listed.
NCT00290134 lists 16 locations in 13 states (New York, Florida, Alabama).
Frequently Asked Questions
What is clinical trial NCT00290134 about?
NCT00290134 is a clinical study titled "A Preliminary Clinical Study to Evaluate Fispemifene in the Treatment of Hypogonadism". The purpose of this study is to determine whether one or more fispemifene dose regimens are more effective than placebo in the treatment of hypogonadism in older men.
What is the current status of trial NCT00290134?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2006-02. Estimated completion is 2007-10.
What conditions does trial NCT00290134 study?
This clinical trial studies the following conditions: Hypogonadism.
What interventions are being tested in trial NCT00290134?
The interventions under investigation include: Fispemifene once daily for 4 weeks (DRUG).
Who is sponsoring clinical trial NCT00290134?
This trial is sponsored by QuatRx Pharmaceuticals Company, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00290134 being conducted?
This trial has 16 study locations across Alabama, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypogonadism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00290134's enrollment target sits among peer trials
100 6th of 21 higher than 16 of 21 other Hypogonadism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypogonadism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury
RECRUITING · Phase 2
-
Pharmacokinetics, Metabolism, Efficacy, and Safety Study of Two Testosterone Matrix Transdermal Systems
COMPLETED · Phase 2
-
Testosterone and Growth Hormone for Bone Loss in Men
COMPLETED · Phase 2
-
28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men
COMPLETED · Phase 2
-
The Effect of Various Amounts of Fat on PK of Oral Testosterone Undecanoate
COMPLETED · Phase 2
-
Observation of Environment and Reproductive-Endocrine Effects
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia